Source comparison
TB-500 Protocol Comparison: Hair Loss vs Injury Recovery
Hair Loss (Researchers) 2–5mg 2–3× weekly 4–8 weeks initial, 1–2mg weekly maintenance Subcutaneous near scalp (within 2–3cm of target area) Dermal papilla stem cell activation, angiogenesis at follicle base, sustained VEGF upregulation Requires sustained moder
This comparison does not assign a generated winner or score.
- Hair Loss (Researchers)
- 2–5mg
- 2–3× weekly
- 4–8 weeks initial, 1–2mg weekly maintenance
- Subcutaneous near scalp (within 2–3cm of target area)
- Dermal papilla stem cell activation, angiogenesis at follicle base, sustained VEGF upregulation
- Requires sustained moderate dosing to maintain follicular signaling. Acute loading phases used in injury protocols do not translate to hair regeneration
- Acute Injury Recovery
- 5–10mg loading, 2.5–5mg maintenance
- Daily for 7–10 days, then 2× weekly
- 4–6 weeks
- Intramuscular or subcutaneous near injury site
- Wound healing, inflammation modulation, acute tissue repair
- High-dose loading optimises acute repair response but is unnecessary and potentially counterproductive for follicular regeneration, which requires sustained low-level activation
- Systemic Anti-Inflammatory
- 2.5–5mg
- 1–2× weekly
- Ongoing
- Intramuscular (deltoid, glute)
- Broad immune modulation, systemic inflammation reduction
- Does not achieve sufficient tissue concentration at the follicle to drive angiogenesis. Hair-specific protocols require localised administration